Hansa Biopharma (Q3 Initial take): Sequential Sales Decline but Clinical Success - Redeye

Redeye provides its initial take on Hansa Biopharma’s Q3 report. Product sales declined sequentially to SEK30m, down from SEK48m in Q2, largely due to fewer transplants during holidays and the pause in the Eurotransplant Program. The US ConfideS study had a positive outcome and Hansa is preparing to submit the BLA to the FDA before this year. Funding improved with the directed issue of USD71m.

Länk till analysen i sin helhet: https://www.redeye.se/research/1134218/hansa-biopharma-q3-initial-take-sequential-sales-decline-but-clinical-success?utm_source=finwire&utm_medium=RSS